

## PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

200r

To:

Kolster Oy Ab  
Iso Roobertinkatu 23 P.O.  
Box 148  
FI-00121 Helsinki  
Finland

PCT

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing 30-05-2005  
(day/month/year)

Applicant's or agent's file reference  
2040146PC/or

FOR FURTHER ACTION  
See paragraph 2 below

International application No.

PCT/FI 2005/000075

International filing date (day/month/year)

04.02.2005

Priority date (day/month/year)

06.02.2004

International Patent Classification (IPC) or both national classification and IPC

A61K31/198, A61K33/00, A61K31/519, A61P17/06

Applicant

Helsingfors Institution för Bioimmunterapi Ab et al

## 1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☒ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☒ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

## 2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further opinions, see Form PCT/ISA/220.

## 3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/SE  
Patent- och registreringsverket  
Box 5055  
S-102 42 STOCKHOLM

Facsimile No. +46 8 667 72 88

Authorized officer

Eva Johansson/El.s

Telephone No. +46 8 782 25 00

Form PCT/ISA/237 (cover sheet) (January 2004)

CORRECTED

EXPRESS MAIL LABEL  
NO.: EV 815 585 328 US

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/FI2005/000075

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement.

## 1. Statement

Novelty (N)	Claims	<u>1-9</u>	YES
	Claims		NO
Inventive step (IS)	Claims	<u>1-9</u>	YES
	Claims		NO
Industrial applicability (IA)	Claims	<u>1-9</u>	YES
	Claims		NO

## 2. Citations and explanations:

The invention relates to the use of L-seine, L-isoleucine, folic acid and trace elements for the manufacture of a pharmaceutical composition for treating or preventing psoriasis.

Documents cited in the International Search Report:

D1: WO 89/01930 A1

D2: Tallberg Thomas. "Development of a Combined Biological and Immunological Cancer Therapy Modality. A review of Bio-Immunotherapy." Journal of Australian Collage of Nutritional & Enviromental Medicine. April 2003, Vol.22, p. 3-21.

D3: IT1299623 B1

D4: US 2004/0086583 A1

D5: GB2370504 A

D6: US5006337 A

The cited documents represent the general state of the art. The invention defined in claims 1-9 is not disclosed by any of these documents.

The cited prior art does not give any indication that would lead a person skilled in the art to the claimed composition. Therefore, the claimed invention is not obvious to a person skilled in the art.

Accordingly, the invention defined in claims 1-9 is novel and is considered to involve an inventive step. The invention is industrially applicable.